

Resource Summary Report

Generated by T1D on Aug 10, 2026

Drug Development Pipeline

RRID:SCR_008464

Type: Tool

Proper Citation

Drug Development Pipeline (RRID:SCR_008464)

Resource Information

URL: <http://www.cff.org/treatments/Pipeline/>

Proper Citation: Drug Development Pipeline (RRID:SCR_008464)

Description: The Cystic Fibrosis Foundation has built a dynamic pipeline for the development of more new potential cystic fibrosis (CF) therapies than ever before. To treat a complex disease like CF, therapies must target problems in the airways and the digestive system. In the CF drug development pipeline, there also are promising new therapies designed to rectify the cause of CF a faulty gene and/or its faulty protein product. Cystic fibrosis is an inherited chronic disease that affects the lungs and digestive system of about 30,000 children and adults in the United States (70,000 worldwide). A defective gene and its protein product cause the body to produce unusually thick, sticky mucus that: clogs the lungs and leads to life-threatening lung infections; and obstructs the pancreas and stops natural enzymes from helping the body break down and absorb food. In the 1950s, few children with cystic fibrosis lived to attend elementary school. Today, advances in research and medical treatments have further enhanced and extended life for children and adults with CF. Many people with the disease can now expect to live into their 30s, 40s and beyond.

Synonyms: Drug Development Pipeline

Resource Type: portal, data or information resource, topical portal

Resource Name: Drug Development Pipeline

Resource ID: SCR_008464

Alternate IDs: nif-0000-30400

Record Creation Time: 20220129T080247+0000

Record Last Update: 20260810T040451+0000

Ratings and Alerts

No rating or validation information has been found for Drug Development Pipeline.

No alerts have been found for Drug Development Pipeline.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#) .

Guerrera IC, et al. (2009) A novel lipidomic strategy reveals plasma phospholipid signatures associated with respiratory disease severity in cystic fibrosis patients. PloS one, 4(11), e7735.

Thelin WR, et al. (2007) The epithelium as a target for therapy in cystic fibrosis. Current opinion in pharmacology, 7(3), 290.